UNSPSC 51333410: Ziprasidone

This classification denotes an antipsychotic agent with the molecular formula C21H21ClN4OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6UKA5VEJ6X, chemically known as 2h-indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro- but generally known as ziprasidone, which bears US NIH Compound Identifier 60854. European Medicines Agency schedules Ziprasidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00168MIG.

UNSPSC 51333410 Ziprasidone, a Commodity code, nominally describes a specific antipsychotic pharmaceutical, but recent state and local solicitations tagged under this code show little direct procurement activity for ziprasidone itself. Instead, the code appears in opportunities spanning broader pharmaceutical procurement — generic multi-source drugs, over-the-counter products, naloxone, and direct-to-manufacturer prescription programs. State and local issuers soliciting under this code include county health departments, state health and human services agencies, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions. The scope of actual buying reflects pharmaceutical supply chain dynamics: jurisdictions are procuring through authorized wholesalers, negotiating pricing models with manufacturers, and seeking vendors capable of managing complex compliance requirements including cGMP certification, Drug Supply Chain Security Act adherence, and FDA compliance.

The geographic spread of recent activity centers on Florida, Texas, and Minnesota, with broader multistate participation through cooperative purchasing. Representative recent opportunities include Seminole County, Florida's IFB for naloxone and drug deactivation systems (posted June 30, 2026, due July 26, 2026), the Texas Health and Human Services Commission's Request for Information on direct-to-manufacturer prescription programs (posted April 3, 2026), and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic pharmaceuticals and OTC products (posted January 20, 2026, due March 26, 2026). The MMCAP solicitation illustrates the scale of cooperative purchasing activity — vendors must supply through designated wholesalers, comply with administrative fee structures (3 percent), and carry $2 million to $5 million in insurance coverage. None of the recent opportunities explicitly references ziprasidone procurement, suggesting the code may be mistagged or represents historical categorization that does not align with current state and local buying patterns.